HANMI PHARM. CO., LTD.

Press Releases Hanmi Pharm. Co., Ltd.

Equities

A128940

KR7128940004

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
316,500 ^KRW	-0.63%		+0.96%	-10.21%

May. 01	Hanmi Pharm Q1 Profit Surges 27.5%, Sales Up 11.8%	MT
Mar. 19	Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allergic Rhinitis Pipeline, Clinical Trials, Key Companies	Nov. 08	AQ
Allergic Rhinitis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-28	AQ
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib First-in-Class Candidate for the Treatment of Intermediate Dry AMD	23-09-26	AQ
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type	23-03-14	AQ
Hanmi Science : Pharmaceutical expects U.S. FDA approval for 2 new drugs	21-01-18	AQ
Hanmi Science : presents solution package strategy to potentially overcome COVID-19 at the 39th JP Morgan Healthcare Conference	21-01-12	AQ
Hanmi Pharm : FDA Grants Fast Track Designation for Hanmi LAPSTriple Agonist	20-07-23	AQ
HanmiPharm : Hanmi/Beijing Hanmi and Innovent Enter into a Global Strategic Partnership to Co-develop a Novel Immuno-oncology Bispecific Antibody	17-03-30	BU
HanmiPharm : Hanmi Pharmaceutical Enters into an Exclusive License Agreement with Genentech for a Novel Oral RAF Inhibitor	16-09-29	BU
HanmiPharm : ZAI Lab and Hanmi Execute a License Agreement to Develop Novel EGFR Targeted Therapy for Lung Cancer in China	15-11-23	BU
HanmiPharm : Hanmi Pharmaceutical Signs an Exclusive License Agreement with Janssen Pharmaceuticals, Inc. to Develop a Novel Biologic for Treatment of Diabetes and Obesity	15-11-09	BU
HanmiPharm : Hanmi Pharmaceutical: Efpeglenatide (GLP-1 Analog), the Promising Potential for Anti-Diabetes/Anti-Obesity Treatment as Once Weekly up to Once Monthly	15-06-08	BU
HanmiPharm : Hanmi Pharmaceutical : Once-Weekly Insulin Combination, ‘LAPSInsulin Combo’, Suggests a New Diabetes Therapeutic Option	15-06-07	BU
HanmiPharm : Hanmi Pharmaceutical to Present Its New Diabetes Drugs Including Quantum Project at 2015 ADA Scientific Sessions	15-06-03	BU
HanmiPharm : Hanmi Pharmaceutical ‘HM61713’ Demonstrated the Effect of Tumor Volume Reduction	15-06-01	BU
HanmiPharm : Hanmi Pharmaceutical to Present Its New Targeted Lung Cancer Drug 'HM61713' at 2015 ASCO Annual Meeting	15-05-28	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer